Published in Proc Natl Acad Sci U S A on January 13, 2011
Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol (2014) 2.73
Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids (2014) 1.49
Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem (2011) 1.30
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A (2013) 1.30
Cell-surface sensors for real-time probing of cellular environments. Nat Nanotechnol (2011) 1.28
Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A (2012) 1.27
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res (2012) 1.24
Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol (2012) 1.21
Aptamer in bioanalytical applications. Anal Chem (2011) 1.21
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev (2012) 1.18
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Monofunctional and higher-valent platinum anticancer agents. Inorg Chem (2013) 1.13
Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat Commun (2014) 1.11
Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med (2012) 1.10
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev (2012) 1.06
DNA aptamer functionalized nanomaterials for intracellular analysis, cancer cell imaging and drug delivery. Curr Opin Chem Biol (2012) 1.05
Cell-specific aptamers as emerging therapeutics. J Nucleic Acids (2011) 1.04
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev (2016) 1.02
Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine (2015) 1.00
Applications of nanotechnology in dermatology. J Invest Dermatol (2012) 1.00
α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano (2012) 1.00
Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb) (2012) 0.99
Polymeric Nanostructures for Imaging and Therapy. Chem Rev (2015) 0.99
Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One (2013) 0.98
Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J Control Release (2013) 0.97
Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc (2014) 0.97
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun (2015) 0.97
Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents. Neoplasia (2013) 0.96
Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages. Mol Ther Nucleic Acids (2013) 0.94
A general RNA motif for cellular transfection. Mol Ther (2012) 0.94
Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93
Bioreducible polycations in nucleic acid delivery: past, present, and future trends. Macromol Biosci (2014) 0.93
New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect. Phys Med (2014) 0.91
Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm (2012) 0.91
Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano (2012) 0.91
Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.90
Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin. PLoS One (2012) 0.90
Aptamer-Drug Conjugates. Bioconjug Chem (2015) 0.89
Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano (2013) 0.88
Cancer research by means of tissue engineering--is there a rationale? J Cell Mol Med (2013) 0.88
Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorg Med Chem Lett (2011) 0.88
Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells. RNA Biol (2012) 0.87
Novel oxidatively activated agents modify DNA and are enhanced by ercc1 silencing. Chem Res Toxicol (2012) 0.87
Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug Chem (2012) 0.87
Synthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cells. J Am Chem Soc (2014) 0.87
Bioengineering strategies for designing targeted cancer therapies. Adv Cancer Res (2013) 0.86
The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs. Inorg Chem (2013) 0.86
Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Sci Rep (2014) 0.85
Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.85
Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol (2014) 0.84
Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano (2013) 0.84
Aptamers: active targeting ligands for cancer diagnosis and therapy. Theranostics (2015) 0.84
Encapsulation of Pt(IV) Prodrugs within a Pt(II) Cage for Drug Delivery. Chem Sci (2015) 0.84
Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells. Chem Commun (Camb) (2014) 0.83
Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin. Int J Nanomedicine (2012) 0.83
PLGA Nanoparticles for Ultrasound-Mediated Gene Delivery to Solid Tumors. J Drug Deliv (2012) 0.83
Stabilized Interleukin-6 receptor binding RNA aptamers. RNA Biol (2013) 0.83
Lipid-coated nanoscale coordination polymers for targeted cisplatin delivery. RSC Adv (2013) 0.82
Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics (2015) 0.82
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett (2012) 0.82
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems. Int J Mol Sci (2015) 0.81
Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond) (2012) 0.81
Recent development of silica nanoparticles as delivery vectors for cancer imaging and therapy. Nanomedicine (2013) 0.81
Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer. Integr Biol (Camb) (2013) 0.81
Antitumor activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in mouse xenograft model of breast cancer. Cell Death Dis (2014) 0.81
Copper-free click-chemistry platform to functionalize cisplatin prodrugs. Chemistry (2014) 0.81
The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate. Chem Sci (2015) 0.80
Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics. Nanomaterials (Basel) (2015) 0.79
Smart Radiation Therapy Biomaterials. Int J Radiat Oncol Biol Phys (2016) 0.79
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update. Pharmaceuticals (Basel) (2016) 0.79
Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles. Int J Nanomedicine (2016) 0.78
Nanotechnology inspired tools for mitochondrial dysfunction related diseases. Adv Drug Deliv Rev (2016) 0.78
A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma. Nucleic Acid Ther (2016) 0.78
Sendai virus-based liposomes enable targeted cytosolic delivery of nanoparticles in brain tumor-derived cells. J Nanobiotechnology (2012) 0.77
Aptamers: A promising chemical antibody for cancer therapy. Oncotarget (2016) 0.77
Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. J Control Release (2017) 0.77
Repression of metadherin inhibits biological behavior of prostate cancer cells and enhances their sensitivity to cisplatin. Mol Med Rep (2015) 0.76
Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment. Small (2015) 0.76
SOST Inhibits Prostate Cancer Invasion. PLoS One (2015) 0.76
EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharm Res (2015) 0.76
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol (2016) 0.76
Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia. Int J Cancer Res Mol Mech (2015) 0.76
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev (2016) 0.75
A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy. J Nanobiotechnology (2015) 0.75
Antiproliferative and apoptotic effect of Morus nigra extract on human prostate cancer cells. Saudi Pharm J (2016) 0.75
In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin. Int J Nanomedicine (2016) 0.75
Radio-frequency plasma polymerized biodegradable carrier for in vivo release of cis-platinum. Oncotarget (2016) 0.75
Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. Am J Cancer Res (2016) 0.75
Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget (2017) 0.75
The influence of p53 mutation status on the anti-cancer effect of cisplatin in oral squamous cell carcinoma cell lines. J Korean Assoc Oral Maxillofac Surg (2016) 0.75
Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse. Mol Cancer Res (2016) 0.75
Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer. Oncotarget (2016) 0.75
Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. Nanomaterials (Basel) (2015) 0.75
Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. Biomark Insights (2016) 0.75
Retracted Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma. Oncotarget (2016) 0.75
K88 Fimbrial Adhesin Targeting of Microspheres Containing Gentamicin Made with Albumin Glycated with Lactose. Int J Mol Sci (2015) 0.75
PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer. Oncotarget (2017) 0.75
MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound. J Control Release (2017) 0.75
Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun (2017) 0.75
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Biodegradable long-circulating polymeric nanospheres. Science (1994) 7.46
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Platinum compounds: a new class of potent antitumour agents. Nature (1969) 5.92
Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev (1999) 5.63
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Blood volume in the rat. J Nucl Med (1985) 3.40
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 2.77
Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc (2008) 2.40
An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl (2006) 2.38
PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release (2002) 2.26
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem (2005) 2.24
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem (2009) 1.73
Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer (1998) 1.61
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem (2007) 1.46
Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res (1997) 1.44
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci U S A (2009) 1.43
Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res (2007) 1.35
Targeted drug delivery via folate receptors. Expert Opin Drug Deliv (2008) 1.33
Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol (2009) 1.02
Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol (1988) 0.97
In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm Biopharm (2008) 0.93
Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats. Acta Pharmacol Sin (2003) 0.83
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Nanoparticle delivery of cancer drugs. Annu Rev Med (2011) 3.75
Synthetic models for non-heme carboxylate-bridged diiron metalloproteins: strategies and tactics. Chem Rev (2004) 3.73
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Direct cellular responses to platinum-induced DNA damage. Chem Rev (2007) 3.42
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc (2007) 2.82
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano (2008) 2.76
Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (2013) 2.61
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc (2008) 2.40
An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl (2006) 2.38
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett (2010) 2.35
Visualization of nitric oxide in living cells by a copper-based fluorescent probe. Nat Chem Biol (2006) 2.33
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials (2008) 2.21
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc (2009) 2.16
Small-molecule fluorescent sensors for investigating zinc metalloneurochemistry. Acc Chem Res (2009) 2.07
Dioxygen activation in soluble methane monooxygenase. Acc Chem Res (2011) 2.07
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev (2010) 1.95
Correlating structure with function in bacterial multicomponent monooxygenases and related diiron proteins. Acc Chem Res (2006) 1.93
Mechanistic studies on the hydroxylation of methane by methane monooxygenase. Chem Rev (2003) 1.89
Cell docking inside microwells within reversibly sealed microfluidic channels for fabricating multiphenotype cell arrays. Lab Chip (2005) 1.89
New metal complexes as potential therapeutics. Curr Opin Chem Biol (2003) 1.89
Inhibition of transcription by platinum antitumor compounds. Metallomics (2009) 1.88
Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett (2008) 1.80
A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. Cancer Res (2010) 1.79
Tools and tactics for the optical detection of mercuric ion. Chem Rev (2008) 1.77
Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA. Chembiochem (2009) 1.71
Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res (2011) 1.71
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol (2004) 1.66
Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A (2010) 1.64
cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A (2008) 1.62
Characterization of the arene-oxidizing intermediate in ToMOH as a diiron(III) species. J Am Chem Soc (2007) 1.60
Imaging mobile zinc in biology. Curr Opin Chem Biol (2010) 1.57
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Water-soluble porphyrins as a dual-function molecular imaging platform for MRI and fluorescence zinc sensing. Proc Natl Acad Sci U S A (2007) 1.53
Consequences of cisplatin binding on nucleosome structure and dynamics. Chem Biol (2010) 1.51
Characterization of the particulate methane monooxygenase metal centers in multiple redox states by X-ray absorption spectroscopy. Inorg Chem (2006) 1.50
Intermediates in dioxygen activation by methane monooxygenase: a QM/MM study. J Am Chem Soc (2007) 1.50
Bacillus anthracis-derived nitric oxide is essential for pathogen virulence and survival in macrophages. Proc Natl Acad Sci U S A (2008) 1.49
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A (2012) 1.48
Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond) (2007) 1.47
Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem (2007) 1.46
Chemical characterization of the smallest S-nitrosothiol, HSNO; cellular cross-talk of H2S and S-nitrosothiols. J Am Chem Soc (2012) 1.46
Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro. Proc Natl Acad Sci U S A (2002) 1.45
Substrate trafficking and dioxygen activation in bacterial multicomponent monooxygenases. Acc Chem Res (2007) 1.43
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci U S A (2009) 1.43
New frontiers in nanotechnology for cancer treatment. Urol Oncol (2008) 1.42
Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem (2007) 1.42
Bacterial nitric-oxide synthases operate without a dedicated redox partner. J Biol Chem (2008) 1.41
The interface of inorganic chemistry and biology. J Am Chem Soc (2010) 1.41
X-ray structure and mechanism of RNA polymerase II stalled at an antineoplastic monofunctional platinum-DNA adduct. Proc Natl Acad Sci U S A (2010) 1.39
Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol (2012) 1.39
X-ray structure of a hydroxylase-regulatory protein complex from a hydrocarbon-oxidizing multicomponent monooxygenase, Pseudomonas sp. OX1 phenol hydroxylase. Biochemistry (2006) 1.38
Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med (2013) 1.38
Micropatterned cell co-cultures using layer-by-layer deposition of extracellular matrix components. Biomaterials (2005) 1.38
Reactions of the peroxo intermediate of soluble methane monooxygenase hydroxylase with ethers. J Am Chem Soc (2005) 1.38
Dioxygen activation in methane monooxygenase: a theoretical study. J Am Chem Soc (2004) 1.38
Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano (2010) 1.35
Modeling the syn disposition of nitrogen donors at the active sites of carboxylate-bridged diiron enzymes. Enforcing dinuclearity and kinetic stability with a 1,2-diethynylbenzene-based ligand. Inorg Chem (2003) 1.35
Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials (2009) 1.35
Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol (2010) 1.35
Membrane-permeable and -impermeable sensors of the Zinpyr family and their application to imaging of hippocampal zinc in vivo. Chem Biol (2004) 1.33
pH-Responsive nanoparticles for drug delivery. Mol Pharm (2010) 1.33
Current challenges of modeling diiron enzyme active sites for dioxygen activation by biomimetic synthetic complexes. Chem Soc Rev (2010) 1.33
Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol (2008) 1.32
Dioxygen activation at non-heme diiron centers: characterization of intermediates in a mutant form of toluene/o-xylene monooxygenase hydroxylase. J Am Chem Soc (2006) 1.32
Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther (2008) 1.30
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A (2013) 1.30
Peripheral heme substituents control the hydrogen-atom abstraction chemistry in cytochromes P450. Proc Natl Acad Sci U S A (2003) 1.30
ZP4, an improved neuronal Zn2+ sensor of the Zinpyr family. J Am Chem Soc (2003) 1.29
Vesicular zinc promotes presynaptic and inhibits postsynaptic long-term potentiation of mossy fiber-CA3 synapse. Neuron (2011) 1.29
New strategy for quantifying biological zinc by a modified zinpyr fluorescence sensor. J Am Chem Soc (2008) 1.28
A tautomeric zinc sensor for ratiometric fluorescence imaging: application to nitric oxide-induced release of intracellular zinc. Proc Natl Acad Sci U S A (2004) 1.27
Nucleotide excision repair from site-specifically platinum-modified nucleosomes. Biochemistry (2003) 1.27
Revisiting the mechanism of dioxygen activation in soluble methane monooxygenase from M. capsulatus (Bath): evidence for a multi-step, proton-dependent reaction pathway. Biochemistry (2009) 1.26
Hydroxylation of methane by non-heme diiron enzymes: molecular orbital analysis of C-H bond activation by reactive intermediate Q. J Am Chem Soc (2002) 1.25
Hydrogen peroxide differentially modulates cardiac myocyte nitric oxide synthesis. Proc Natl Acad Sci U S A (2011) 1.25
Carboxylate as the protonation site in (Peroxo)diiron(III) model complexes of soluble methane monooxygenase and related diiron proteins. J Am Chem Soc (2010) 1.24
Modeling dioxygen-activating centers in non-heme diiron enzymes: carboxylate shifts in diiron(II) complexes supported by sterically hindered carboxylate ligands. Inorg Chem (2002) 1.24
Direct detection of nitroxyl in aqueous solution using a tripodal copper(II) BODIPY complex. J Am Chem Soc (2010) 1.23
Bright fluorescent chemosensor platforms for imaging endogenous pools of neuronal zinc. Chem Biol (2004) 1.22
Bioinspired multivalent DNA network for capture and release of cells. Proc Natl Acad Sci U S A (2012) 1.21
Biochemistry of mobile zinc and nitric oxide revealed by fluorescent sensors. Annu Rev Biochem (2011) 1.21
Metal-based turn-on fluorescent probes for sensing nitric oxide. Acc Chem Res (2007) 1.20
Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials (2011) 1.20
Product bound structures of the soluble methane monooxygenase hydroxylase from Methylococcus capsulatus (Bath): protein motion in the alpha-subunit. J Am Chem Soc (2005) 1.19